Bionox

Bionox is a South Korean clinical-stage biotechnology company dedicated to developing innovative cancer immunotherapies through its proprietary Bio-Nitric Oxide (B-NO) platform. The company's core technology focuses on the controlled delivery of nitric oxide to the tumor microenvironment to enhance immune responses against cancer cells. Its lead program, BN-101, is a first-in-class small molecule nitric oxide donor currently in Phase 1/2a clinical trials for patients with advanced solid tumors. By modulating the immunosuppressive environment of tumors, Bionox aims to improve the efficacy of existing treatments like PD-1/PD-L1 inhibitors. The company is positioning itself as a leader in nitric oxide-based therapeutics within the global oncology market.